ID   OV-3331
AC   CVCL_A1SQ
SY   OV3331
DR   Wikidata; Q105510517
RX   PubMed=32784519;
CC   Doubling time: 2.7 +- 0.3 days (PubMed=32784519).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Asn210Lysfs*37 (c.630del); Zygosity=Unspecified (PubMed=32784519).
CC   Omics: Deep exome analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Miscellaneous: STR profile from personal communication of Mes-Masson A.-M.
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
ST   Source(s): Direct_author_submission
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 11
ST   D16S539: 11
ST   D21S11: 28
ST   D5S818: 12
ST   D7S820: 8,11
ST   TH01: 7
ST   TPOX: 8
ST   vWA: 16,19
DI   NCIt; C7700; Ovarian adenocarcinoma
DI   ORDO; Orphanet_213504; Adenocarcinoma of ovary
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   72Y
CA   Cancer cell line
DT   Created: 12-01-21; Last updated: 29-06-23; Version: 4
//
RX   PubMed=32784519; DOI=10.3390/cancers12082222;
RA   Sauriol A., Simeone K., Portelance L., Meunier L.,
RA   Leclerc-Desaulniers K., de Ladurantaye M., Chergui M.,
RA   Kendall-Dupont J., Rahimi K., Carmona E., Provencher D.M.,
RA   Mes-Masson A.-M.;
RT   "Modeling the diversity of epithelial ovarian cancer through ten novel
RT   well characterized cell lines covering multiple subtypes of the
RT   disease.";
RL   Cancers (Basel) 12:2222.1-2222.26(2020).
//